Methods of treating flt3-mutated hematologic cancers
OwnerBhavana BHATNAGAR, Sharyn D. BAKERinventors
Life of this patent
Estimating the term…
Abstract
Methods to inhibit FLT3 activity in a subject or a cell with an FLT3 mutation are provided. Methods of treating a hematologic cancer, such as acute myeloid leukemia, in a subject identified as having an FLT3 mutation, are also provided.
Claims35
A method for treating a hematologic cancer, the method comprising:
- administering an effective amount of a therapeutic agent having inhibitory activity against Janus kinase 2 (JAK2) and fms-like tyrosine kinase 3 (FLT3) to a subject having a predetermined genetic profile comprising an FLT3 mutation.
5-6. (canceled)
8-9. (canceled)
(canceled)
13-15. (canceled)
17-18. (canceled)
(canceled)
(canceled)
A method for treating acute myeloid leukemia, the method comprising:
- administering an effective amount of pacritinib, or a pharmaceutically acceptable salt, prodrug, or N-oxide thereof to a subject having a predetermined mutation in FLT3, the mutation comprising:
- i. an internal tandem duplication (ITD) mutation;
- and/or
- ii. a tyrosine kinase domain (TKD) mutation.
27-36. (canceled)
38-43. (canceled)
A method of selecting a treatment regimen for a subject in need of treatment for a hematologic cancer, the method comprising:
- receiving a genetic profile for the subject, the genetic profile comprising an FLT3 mutation;
- and
- selecting a treatment regimen based on the genetic profile, the treatment regimen comprising a therapeutic agent having inhibitory activity against Janus kinase 2 (JAK2) and fms-like tyrosine kinase 3 (FLT3).
(canceled)
48-55. (canceled)
57-61. (canceled)
63-68. (canceled)
70-80. (canceled)
Dependencies are inferred from the claim text.